risperidone has been researched along with haloperidol decanoate in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Conley, RR; Kelly, DL; Love, RC; Moore, DB; Sherr, JD | 1 |
| Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M | 1 |
| McEvoy, JP | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS | 1 |
| Gen, K; Suzuki, H | 1 |
| Bø, CN; Einarson, TR; Hemels, ME; Jensen, R; Piwko, C; Pudas, H; Vicente, C; Zilbershtein, R | 1 |
| De Vos, C; Decuypere, F; Denee, TR; Geerts, P; Lamotte, M; Malfait, B; Mulder, CL; Sermon, J | 1 |
| Tagne Nouemssi, AB | 1 |
| Ansolabehere, X; Guillon, P; Harmand, S | 1 |
2 review(s) available for risperidone and haloperidol decanoate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; Injections, Intramuscular; Microspheres; Quality of Life; Risk Assessment; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Refusal | 2006 |
3 trial(s) available for risperidone and haloperidol decanoate
| Article | Year |
|---|---|
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 2004 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Hyperprolactinemia; Injections; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Microspheres; Middle Aged; Patient Compliance; Proportional Hazards Models; Risperidone; Schizophrenia; Weight Gain | 2012 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Computer-Assisted; Executive Function; Female; Haloperidol; Humans; Injections; Male; Memory; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Treatment Outcome | 2012 |
6 other study(ies) available for risperidone and haloperidol decanoate
| Article | Year |
|---|---|
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival; Female; Fluphenazine; Haloperidol; Humans; Length of Stay; Male; Patient Readmission; Risperidone; Schizophrenia; Time Factors | 1998 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Female; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Length of Stay; Male; Microspheres; Middle Aged; Patient Discharge; Proportional Hazards Models; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Models, Econometric; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Sweden | 2014 |
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Topics: Adult; Antipsychotic Agents; Belgium; Benzodiazepines; Delayed-Action Preparations; Drug Administration Schedule; Female; Haloperidol; Humans; Medication Adherence; Netherlands; Olanzapine; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome | 2017 |
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloperidol; Humans; Male; Paliperidone Palmitate; Risperidone; Schizophrenia; Tachycardia, Sinus; Treatment Outcome; Young Adult | 2018 |
Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
.
Topics: Antipsychotic Agents; Delayed-Action Preparations; France; Haloperidol; Humans; Injections; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia | 2019 |